ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Project Information

UNITE4TB

Grant agreement ID: 101007873

DOI 10.3030/101007873

EC signature date 29 June 2021

Start date 1 June 2021

End date 31 May 2028

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 185 000 000,00

EU contribution € 92 500 000,00

Coordinated by

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Deliverables

Documents, reports (6)

Report of kick-off meeting

Report of kickoff meeting

Communication and dissemination plan
Establish CAG
Establish SAB and RAB
Report of first annual consortium meeting
Establish EAB

Other (2)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Websites, patent fillings, videos etc. (1)

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Publications

Peer reviewed articles (5)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Author(s): Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Published in: Pharmaceutics, 2022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Tuberculosis: current challenges and beyond

Author(s): Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Published in: Breath, 2023, ISSN 2073-4735
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Author(s): Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Published in: Clinical Microbiology Reviews, Issue 21 March 2022, 2022, Page(s) n/a, ISSN 1098-6618
Publisher: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Author(s): Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Published in: Breath, 2023, ISSN 2073-4735
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Author(s): Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Published in: Front. Pharmacol., 2023, ISSN 1663-9812
Publisher: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Author(s): Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Published in: International Union Against Tuberculosis and Lung Disease, Issue Volume 25, Number 11, 1 November 2021, 2021, Page(s) 886-889, ISSN 1027-3719
Publisher: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515